IGC-501 / IGC Pharma - LARVOL DELTA

IGC Pharma Receives Notice of Allowance for Patent on Seizures (Businesswire) - "IGC Pharma...today announced that it has received a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (IGC-501). The formulation also received an intent to grant from the European Patent Office. With these awards, and a previous one, the formulation for treating seizures is protected in the U.S., Canada, and certain European countries."

Patent • CNS Disorders • Epilepsy • Pain

IGC Receives Another Patent for a Cannabinoid-Based Cream for Treating Pain (Businesswire) - "India Globalization.. the Company received one more patent (patent#10,933,082) from the United States Patent and Trademark Office ('USPTO') for the Company’s cannabinoid composition and method for treating pain in patients with Psoriatic Arthritis, Fibromyalgia, Scleroderma and other conditions. The patent application was filed on October 1, 2018."

Patent • Musculoskeletal Pain • Pain • Psoriatic Arthritis • Scleroderma